AIM: To describe drugs used in renal cell carcinoma.
METHOD: Pubmed search for efficacy, mode of action and side effects for each molecule. Additional data were searched from the French regulatory agencies websites (HAS and ANSM).
RESULTS: Since 2007, a total of three different therapeutic classes in the management of metastatic renal cell carcinoma are available. These three classes are tyrosine kinase inhibitors with sunitinib and sorafenib, the anti-VEGF antibodies (bevacizumab which is associated with alpha interferon in the treatment of advanced kidney cancer) and mTOR inhibitors with temsirolimus and everolimus. These targeted therapies are a major progress in the treatment of patients with metastatic kidney cancer. The side effects encountered with these molecules are numerous but serious side effects are less than 5% of all reported side effects.
CONCLUSIONS: A better understanding of molecular mechanisms has enabled the development of new therapies for the treatment of metastatic renal cell carcinoma. In the future, a personalized approach taking into account the biology of each tumor could be created to provide a more targeted treatment.
Written by:
Guy L, Bay JO, Bastide C, Mahammedi H, Bruyere F, Karsenty G. Are you the author?
Faculté de médecine, université d'Auvergne, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand cedex 1, France; Service d'urologie, hôpital G.-Montpied, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France.
Reference: Prog Urol. 2013 Nov;23(15):1225-37.
doi: 10.1016/j.purol.2013.09.011
PubMed Abstract
PMID: 24183081
Article in French.
UroToday.com Renal Cancer Section
